Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Banner

Enterprise Ireland Start-up Day 2024

May 17th 2024

Read More

Banner

SHORLA ONCOLOGY TO ATTEND ASEMBIA24

April 24th 2024April 24th 2024

Read More

Sharon Cunningham

MassBio | SHARON CUNNINGHAM

April 24th 2024April 24th 2024

Read More

Banner

Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year Finalists

April 24th 2024

Read More

Photo

A Milestone for Shorla Oncology

April 22nd 2024

Read More

Logo

FDA Considers SH-201 for Treating Certain Leukemias and Cancers

April 22nd 2024

Read More

Oncology Live Logo

FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

July 18th 2025April 22nd 2024

Read More

Logo

FDA Accepts Shorla’s NDA for SH-201 to Treat Leukemia and Other Cancers

April 22nd 2024

Read More

Orlaith EI Panel

Scaling Your Business Panel Participation

April 22nd 2024

Read More

Older posts
Newer posts
Page1 … Page6 Page7 Page8 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.